Depo-subq Provera 104 is a drug owned by Pfizer Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 15, 2020. Details of Depo-subq Provera 104's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6495534 | Stabilized aqueous suspensions for parenteral use |
May, 2020
(6 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but
Depo-subq Provera 104 is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Depo-subq Provera 104's family patents as well as insights into
ongoing legal events
on those patents.
Depo-subq Provera 104's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Depo-subq Provera 104:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months | Bayer | NA | WITHDRAWN
(Jul 22, 2026) | PHASE3 |
| Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia | Peking University People's Hospital | NA | NOT YET RECRUITING
(Jul 1, 2026) | PHASE2 |
| Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma | Xiaojun Chen | NA | TERMINATED
(Jun 1, 2026) | PHASE2, PHASE3 |
| TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC | Fudan University | NA | RECRUITING
(Jun 1, 2026) | PHASE2 |
| Intrauterine Injection of Type III Collage in FST of EC/AEH | Wang Jianliu | NA | RECRUITING
(Mar 1, 2026) | PHASE2 |
Generic Launch
Generic Release Date:
Depo-subq Provera 104's generic launch date based on the expiry of its last outstanding patent is estimated to be May 15, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Depo-subq Provera 104 Generic API suppliers:
Medroxyprogesterone Acetate is the generic name for the brand Depo-subq Provera 104. 16 different companies have already filed for the generic of Depo-subq Provera 104, with Duramed Pharms Barr having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Depo-subq Provera 104's generic
Alternative Brands for Depo-subq Provera 104
There are several other brand drugs using the same active ingredient (Medroxyprogesterone Acetate) as Depo-subq Provera 104. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Wyeth Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Medroxyprogesterone Acetate, Depo-subq Provera 104's active ingredient. Check the complete list of approved generic manufacturers for Depo-subq Provera 104
About Depo-subq Provera 104
Depo-Subq Provera 104 is a drug owned by Pfizer Inc. Depo-Subq Provera 104 uses Medroxyprogesterone Acetate as an active ingredient. Depo-Subq Provera 104 was launched by Pfizer in 2004.
Approval Date:
Depo-subq Provera 104 was approved by FDA for market use on 17 December, 2004.
Active Ingredient:
Depo-subq Provera 104 uses Medroxyprogesterone Acetate as the active ingredient. Check out other Drugs and Companies using Medroxyprogesterone Acetate ingredient
Dosage:
Depo-subq Provera 104 is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 104MG/0.65ML | INJECTABLE | Prescription | SUBCUTANEOUS |